MSH3

Somatic CRISPR editing of Msh3 mitigates Huntington's disease pathology in mice.

Maladie de Huntington

Heterozygous germline mutations in MSH3, and probably MLH3, act as classical tumour suppressors, leading to excess somatic deletion mutations, signature ID4 and increased colorectal cancer risk.

Cancer colorectal et polypose multiple

Heterozygous germline MSH3 mutations, and probably MLH3 mutations, act as classical tumour suppressors, leading to excess somatic deletion mutations, signature ID4 and increased colorectal cancer risk

Cancer colorectal héréditaire — déficit en MSH3 ou MLH3